Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 103-109

  Meier, Emily Riehm ^a,b   Byrnes, Colleen ^a   Weissman, Maxine ^c   Noel, Pierre ^c   Luban, Naomi L C ^b,d   Miller, Jeffery L ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

F cells; Fetal hemoglobin; Sickle cell disease

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CELLULAR DISTRIBUTION; CHILD; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FETUS CELL; GENE SILENCING; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SICKLE CELL ANEMIA;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE COUNT; ERYTHROCYTES, ABNORMAL; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; INFANT; YOUNG ADULT;

EID: 78649666290     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22643     Document Type: Article

References (23)

1. Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood 1994; 84: 3182-3188.
2. Brown AK, Sleeper LA, Miller ST, et al. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med 1994; 148: 796-804.
3. Emond AM, Cloois R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: Natural history and management. J Pediatr 1985; 107: 201-206.
4. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340: 1021-1030.
5. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical and therapeutic considerations. Semin Hematol 1991; 28: 213-219.
6. Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006; 108: 1073-1076.
7. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
8. Franco RS, Lohmann J, Silberstein EB, et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest 1998; 101: 2730-2740.
9. Stevens MC, Hayes RJ, Vaidya S, et al. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr 1981; 98: 37-41.
10. Powars DR, Weiss JN, Chan LS, et al. Is there a threshold of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984; 63: 921-926.
11. Noguchi CT, Rodgers GP, Serjeant G, et al. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988; 318: 96-99.
12. Oneal PA, Gantt NM, Schwartz JD, et al. Fetal hemoglobin silencing in humans. Blood 2006; 108: 2081-2086.
13. Gaston M, Rosse WF. The cooperative study of sickle cell disease: Review of study design and objectives. Am J Pediatr Hematol Oncol 1982; 4: 197-201.
14. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332: 1317-1322.
15. Marcus SJ, Kinney TR, Schultz WH, et al. Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. Am J Hematol 1997; 54: 40-46.
16. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008; 122: 1332-1342.
17. Hoffman R, Benz EJ, Shattil SJ, et al. editors. Hematology: Basic principles and practice, 5th edition. Philadelphia: Churchill Livingstone Elsevier; 2008. p. 2442.
18. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol 2005; 33: 259-271.
19. Marcus SJ, Ware RE. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: Implications for pharmacological intervention. J Pediatr Hematol Oncol 1999; 21: 407-411.
20. Chakalova L, Carter D, Debrand E, et al. Developmental regulation of the beta-globin gene locus. Prog Mol Subcell Biol 2005; 38: 183-206.
21. Wood WG, Bunch C, Kelly S, et al. Control of haemoglobin switching by a developmental clock? Nature 1985; 313: 320-323.
22. Bozzini CE, Alippi RM, Barcelo AC, et al. The biology of stress erythropoiesis and erythropoietin production. Ann NY Acad Sci 1994; 718: 83-92.
23. Pashankar FD, Carbonella J, Bazzy-Asaad A, et al. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol 2009; 144: 736-741.